About NeuroNova
NeuroNova is develops drug targets and candidates that demonstrate potential in the treatment of neurodegenerative diseases. Its products include sNN0029, a drug candidate for the treatment of amyotrophic lateral sclerosis; and sNN0031, a drug candidate for the treatment of moderate to severe stage Parkinson’s disease that is designed to act on neural stem and progenitor cells in the brain.
Facts about NeuroNova
Facts about NeuroNova
- Focus : Manufacturer
- Industry : Pharma